Ad hoc announcement pursuant to Art. 53 LR Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care

Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous trials.“Since 40% of people with DLBCL relapse after initial therapy, achieving meaningful treatment effects in the front-line setting has the potential to be transformative,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This Polivy regimen is the first in two decades to improve progression-free survival in DLBCL compared to the standard of care, and we look forward to sharing these results with health authorities to bring this important potential new treatment option to patients as soon as possible.”Today ’s POLARIX results will be presented at an upcoming medical meeting and submitted to health authorities as part of Roche’s commitment to transforming the treatment of DLBCL by providing options tailored to patient and healthcare professional needs. Roche w...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

In response to increasing dependence on US Medical Licensing Examination Step 1 scores for resident selection, and to improve medical student well-being and education, the Federation of State Medical Boards and the National Board of Medical Examiners announced that no sooner than 2022, Step 1 score reporting would change from numeric to pass/fail. To gauge the impact that this change will have on the residency application process in physical medicine and rehabilitation, an anonymous survey was electronically distributed to program directors of all accredited physical medicine and rehabilitation residency programs in the Un...
Source: American Journal of Physical Medicine and Rehabilitation - Category: Rehabilitation Tags: Education & Administration Source Type: research
Conclusions: Changes could be due to individual state practices.
Source: Journal of Nursing Care Quality - Category: Nursing Tags: Articles Source Type: research
HEART disease: Around twice as many people are living with heart and circulatory diseases in the UK than with cancer and Alzheimer's disease combined according to the British Heart Foundation. Could a seemingly innocent and popular drug be contributing to these shocking statistics?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
France has just made boosters available for everyone over 18, as long as it has been 5 months since their second dose. Those who are not vaccinated by mid-January risk losing their pass sanitaire.Medscape Medical News
Source: Medscape Infectious Diseases Headlines - Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
Conclusions: Diabetes is significantly associated with higher risk of mortality and MACCE; however, prediabetes did not show a prognostic impact in terms of overall and MACCE-free survival.
Source: Critical Pathways in Cardiology - Category: Cardiology Tags: Original Study Source Type: research
AbstractGasdermins (GSDM) are members of a family of pore-forming effector proteins which lead to membrane permeabilization and pyroptosis, a lytic cell death with pro-inflammatory characteristics. Recently, two members of the gasdermin family, gasdermin B (GSDMB) and gasdermin E (GSDME), were shown to suppress tumor growth, through the involvement of cytotoxic lymphocytes. Other studies also reported the important functions of gasdermins in various cancer types including gastric cancer, hepatocarcinoma, and cervix and breast cancer. However, gasdermins have not been previously studied in the context of serous ovarian canc...
Source: Inflammation - Category: Allergy & Immunology Source Type: research
This study provides pilot data for the further development ofL. casei exoproducts as an anti-inflammatory or anti-proliferative agent for the treatment of inflammatory and cancer diseases in gut. However, more data is needed before final conclusions ofL. casei cell-free supernatant ’s efficacy can be drawn.
Source: Inflammation - Category: Allergy & Immunology Source Type: research
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Academia | Allergy & Immunology | Belgium Health | Biotechnology | Cancer | Cancer & Oncology | Diabetes | Eloxatin | Endocrinology | Food and Drug Administration (FDA) | France Health | Hodgkin's Disease | Infectious Diseases | International Medicine & Public Health | Internet | Israel Health | Japan Health | Leukemia | Lymphoma | Men | Middle East Health | Molecular Biology | Non-Hodgkin's Lymphoma | Opthalmology | Partnerships | Pharmaceuticals | Portugal Health | Prednisone | Primary CNS Lymphoma | Rituxan | Science | Study | Switzerland Health | Treanda | USA Health | WHO